Table 3 Factors associated with MR, and neurocognitive deficits at discharge and at D21–D28.
From: Determinants of retinopathy and short-term neurological outcomes after cerebral malaria
Variables | With MR n = 32 | p-value | NeuroCognitive deficits screener positive at discharge n = 24 | p-value | NeuroCognitive deficits screener positive at D21–D28 n = 7 | p-value |
|---|---|---|---|---|---|---|
Age (n = 58) | 0.376 | 0.921 | 0.390 | |||
4 years old or less | 19/36 (52.8%) | 16/33 (48.5%) | 6/27 (22.2%) | |||
More than 4 years old | 11/22 (65.0%) | 8/16 (50.0%) | 1/17 (6.7%) | |||
Gender (n = 56) | 0.385 | 0.913 | 0.099 | |||
Female | 21/34 (61.8%) | 15/31 (48.4%) | 2/25 (0.1%) | |||
Male | 11/22 (50%) | 9/18 (50.0%) | 5/17 (29.4%) | |||
Admitting hospital (n = 56) | 0.054 | 0.316 | 0.679 | |||
Calavi | 13/29 (44.8%) | 10/24 (41.7%) | 2/18 (11.1%) | |||
CHUMEL | 19/27 (70.3%) | 14/25 (56.0%) | 5/24 (20.8%) | |||
Medical consultation (n = 56) | 0.446 | 1.000 | 0.067 | |||
Yes | 29/49 (59.2%) | 22/45 (48.9%) | 5/39 (12.8%) | |||
No | 3/7 (42.9%) | 2/4 (50.0%) | 2/3 (66.7%) | |||
Traditional consultation (n = 55) | 0.003* | 0.905 | 0.225 | |||
Yes | 18/22 (81.8%) | 10/20 (50.0%) | 4/15 (26.7%) | |||
No | 14/33 (42.4%) | 14/29 (48.3%) | 3/27 (11.1%) | |||
Pre-admission treatment | ||||||
Antibiotic (n = 56) | 0.670 | 0.083 | 0.075 | |||
Yes | 21/38 (55.3%) | 19/33 (57.6%) | 7/28 (25.0%) | |||
No | 11/18 (61.1%) | 5/16 (31.2%) | 0/14 (0.0%) | |||
Anti-epileptic (n = 55) | 0.013* | 0.562 | 0.093 | |||
Yes | 10/25 (40.0%) | 12/22 (54.6%) | 6/21 (28.6%) | |||
No | 22/30 (73.3%) | 12/26 (46.2%) | 1/21 (4.8%) | |||
Onset of illness with coma (n = 56) | 0.641 | 1.000 | 1.000 | |||
Yes | 30/51 (58.8%) | 22/45 (48.9%) | 7/39 (17.9%) | |||
No | 2/5 (40%) | 2/4 (50.0%) | 0/3 (0.0%) | |||
Clinical and biological examinations | ||||||
Blantyre’s score (n = 56) | 0.573 | 0.496 | 1.000 | |||
2 | 26/44 (59.1%) | 18/39 (46.2%) | 6/33 (11.1%) | |||
0 or 1 | 6/12 (50%) | 6/10 (60.0%) | 1/9 (11.1%) | |||
Multiple convulsions (n = 55) | 0.210 | 0.083 | 0.410 | |||
Yes | 18/27 (66.8%) | 9/24 (62.5%) | 5/21 (23.8%) | |||
No | 14/28 (50%) | 9/24 (37.5%) | 2/20 (10.0%) | |||
Respiratory distress (n = 56) | 0.361 | 0.725 | 0.312 | |||
Yes | 6/13 (46.1%) | 5/9 (55.6%) | 0/8 (0.0%) | |||
No | 26/43 (60.5%) | 19/40 (47.5%) | 7/34 (20.6%) | |||
Jaundice§ (n = 55) | 0.262 | 0.017* | 0.089 | |||
Yes | 15/23 (65.2%) | 13/18 (72.2%) | 5/16 (31.2%) | |||
No | 16/32 (50.0%) | 11/31 (36.7%) | 2/25 (8.0%) | |||
Hypoglycaemia§ (n = 56) | 0.338 | 0.675 | 0.113 | |||
Yes | 7/15 (46.7%) | 6/11 (54.6%) | 3/8 (37.5%) | |||
No | 25/41 (61.0%) | 18/38 (47.4%) | 4/34 (11.8%) | |||
Acidosis§ (n = 55) | 0.660 | 1.000 | 1.000 | |||
Yes | 13/21 (61.9%) | 8/16 (50.0%) | 2/14 (37.5%) | |||
No | 19/34 (55.9%) | 16/32 (50.0%) | 5/27 (11.8%) | |||
Severe anaemia§ (n = 56) | 0.014* | 0.905 | 1.000 | |||
Yes | 17/22 (77.3%) | 10/20 (50.0%) | 3/18 (16.7%) | |||
No | 15/34 (44.1%) | 14/29 (48.3%) | 4/24 (16.7%) | |||
MR (n = 32) | 0.005* | 0.222 | ||||
Yes | 19/29 (25.0%) | 6/26 (23.1%) | ||||
No | 5/20 (65.5%) | 1/16 (6.3%) |
